Research and Markets: IMS Pharmaceutical Pricing & Reimbursement Concise 2011 Guide: Argentina Covers Key Developments in

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/830ba5/ims_pharmaceutical) has announced the addition of the "IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Argentina" report to their offering.

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Key Topics Covered:

  • HEALTHCARE SYSTEM
  • PRICING
  • Prescription Drugs
  • Generic Drugs
  • Hospital Drugs
  • OTC Drugs
  • REIMBURSEMENT
  • Admission to Reimbursement
  • Reimbursement Categories
  • Reimbursement Prices
  • Hospital Reimbursement
  • Changes in Reimbursement Status
  • Changes in Reimbursement Prices
  • PHARMACOECONOMICS
  • Pharmacoeconomic Requirements
  • Price Build Up
  • Wholesalers Retail Pharmacies
  • Dispensing Doctors
  • Sales Tax
  • COST CONTAINMENT
  • Industry Paybacks
  • Promotional Costs
  • Patient Co-payments
  • Prescribing Controls
  • Generics
  • Rx-to-OTC Switches
  • Parallel Trade
  • FUTURE DEVELOPMENTS
  • Outlook
  • NAMES & ADDRESSES

For more information visit http://www.researchandmarkets.com/research/830ba5/ims_pharmaceutical

Source: IMS Health



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Argentina  Europe  South America  Ireland

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

German viral vector CDMO Vibalogics has hired Lonza veteran Tom Hochuli as global CEO to help lead its U.S. expansion efforts.

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.